Genes mapping to approved or investigational drugs included CALCRL (target of several medications used to manage migraine disorder), LAMC1 (target of ocriplasmin, used to treat vitreomacular traction), and ANGPTL4 (investigational target for hypertriglyceridemia). This evidence concerns the gene ANGPTL4 and hypertriglyceridemia.